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Summary We analysed outcome in 206 consecutive male patients treated for metastatic non-seminomatous
germ cell tumour (NSGCT) of testicular or extragonadal origin treated with the POMB/ACE (cisplatin,
vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) regimen after division into
prognostic groups by commonly used clinical classification systems and definitions of adverse prognosis. The
adverse prognostic groups of all classification systems and definitions examined showed similar, but only
moderate, sensitivity (71-81%) and specificity (52-56%) in predicting death. A simple definition of poor
prognosis based on raised initial levels of serum tumour markers alpha fetoprotein (aFP) and human
chorionic gonadotrophin (hCG) proved at least as useful (sensitivity 80%, specificity 55%) as other more
complicated systems in predicting failure to achieve long-term survival. Comparison of survival between ultra-
high dose cisplatin-based combination chemotherapy and patients treated with POMB/ACE shows no
advantage from this more toxic approach. This suggests that good results in adverse prognosis patients can be
achieved using conventional dose regimens administered intensively.
Cisplatin-based combination chemotherapy is the standard
treatment for metastatic non-seminomatous germ cell
tumours (NSGCT) of testicular or extragonadal origin and
many reports exist of successful therapy using regimens
incorporating various combinations of cisplatin (DDP), vin-
blastine, bleomycin (BLM), etoposide (VP16), doxorubicin,
cyclophosphamide and several other agents (Einhorn et al.,
1985). Uniformly high rates of complete response and long-
term survival are described among patients with so-called
'good prognosis' or 'minimal risk' metastatic disease
(Williams et al., 1987; Newlands et al., 1986; Logothetis et
al., 1986; Bosl et al., 1986). However, the relative merits of
more dose-intensive regimens claimed to produce better
results in 'poor prognosis' NSGCT (Newlands et al., 1986;
Logothetis et al., 1986; Daugaard & Rorth, 1986; Ozols,
1987; Schmoll et al., 1987) are difficult to interpret for two
main reasons: (i) lack of uniform staging criteria or prognos-
tic indices in published series, and (ii) improved results from
older combinations as physician familiarity with DDP-based
chemotherapy increased (Medical Research Council Working
Party on Testicular Tumours, 1985; Einhorn, 1986).
Traditionally, testicular cancer staging in North America
has followed Samuels' M.D. Anderson Hospital system
(MDA) with patients divided into minimal and advanced
categories for prognostic purposes (Logothetis et al., 1986).
Einhorn's group from Indiana University (IND) developed a
three-tiered system (minimal, moderate and advanced) which
appears to delineate an adverse prognosis group more accu-
rately (Einhorn et al., 1985; Williams et al., 1987). Royal
Marsden Hospital staging (RMH) separates patients into
small and large volume prognostic groups and is used widely
in the United Kingdom and Europe (Peckham, 1981).
All these systems are based on site and bulk of metastatic
disease judged by clinical and radiological criteria. However,
Germa-Lluch et al. (1980) showed initial serum levels of
tumour markers (alpha fetoprotein, aFP; human chorionic
gonadotrophin, hCG) correlated with survival in patients
treated for advanced NSGCT and Vugrin et al. (1984) later
reported similar correlation between marker levels and treat-
ment response. A multicentre retrospective analysis of pro-
gnostic factors in metastatic NSGCT by the Medical
Research Council (MRC) Working Party on Testicular
Tumours (1985) divided patients into three prognostic cate-
gories (low, intermediate and high risk) using clinical and
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radiological assessment of disease site and bulk plus initial
serum marker (aFP, hCG) levels. At Charing Cross Hospital
(CXH) we have used RMH staging in reporting our results
but have also defined good and poor prognostic groups by
initial marker (aFP, hCG) levels only, regardless of clinical
or radiological extent of metastatic disease (Newlands et al.,
1986; Begent & Bagshawe, 1983).
Other investigators have produced prognostic equations
from retrospective multiple regression analyses of pretreat-
ment factors in patients with metastatic NSGCT (Bosl et al.,
1983; Birch et al., 1986) while the European Organization for
Research on Treatment of Cancer (EORTC) defined four
prognostic groups using similar methods (Stoter et al., 1987).
High initial serum hCG level appears the most important
predictor of poor prognosis from these studies.
In this paper, we review 10 years' single institution
experience with metastatic NSGCT treated using the POMB/
ACE regimen (Newlands et al., 1986). All patients were
reclassified according to a number of published staging and
prognostic criteria aiming to define the relative value of
these commonly used clinical systems in predicting long-term
outcome as well as the efficacy of POMB/ACE in poor
prognosis metastatic NSGCT.
Patients and methods
Records from 237 patients with metastatic testicular and
extragonadal NSGCT treated between May 1977 and Febru-
ary 1988 were examined. All received first-line chemotherapy
with the POMB/ACE regimen described previously (New-
lands et al., 1986). When this regimen was first used, only
two courses of POMB (total DDP dose 240mgm2) were
given but it was soon apparent that larger DDP doses were
necessary to maximise response rate in advanced disease.
Outcome in 31 patients who received the less intensive
treatment has been reported (Newlands et al., 1986) and
those patients were not included in this series, which com-
prises 206 consecutive cases of metastatic NSGCT treated
with at least three courses of POMB (minimum DDP dose
360mgm 2) since April 1979 (for administration of POMB/
ACE chemotherapy see the Appendix).
Histological diagnosis of NSGCT was made from primary
lesion or metastatic deposit (British Testicular Tumour
Panel, BTTP, criteria (Pugh, 1976)) in most patients. Mixed
tumours were classified by predominant histological type and
regarded as NSGCT where seminoma co-existed with non-
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seminoma. Patients with pure seminoma but persistently
raised or increasing markers, i.e. aFP> 10kU 1-1 (normal
range: 0-l0kUl-1) or hCG>100IUP1- (normal range: 0-
4IUI1- where I ngml- I =5 IU1-1), were treated as NSGCT
and are included in this analysis. There were 20 patients with
extragonadal primaries (12 retroperitoneal and 8 mediasti-
nal). A few patients presented with widespread metastatic
deposits plus very high markers (aFP,hCG) but no obvious
site of primary tumour. A presumptive diagnosis of NSGCT
was made without histological confirmation in such cases.
No patient with very advanced disease was excluded from
analysis because of poor clinical condition at presentation.
All patients were assessed initially by physical examination,
serum and cerebrospinal fluid levels of aFP and hCG, chest
X-ray, conventional whole lung tomography or computerised
tomography (CT) of thorax, plus abdominal and pelvic
ultrasound and/or CT. Some patients had other investi-
gations, including bipedal lymphography, radionuclide liver
scan and CT brain.
Extent of metastatic disease at initiation of chemotherapy
was used to classify our patients according to the systems of
(i) MDA (Logothetis et al., 1986) (Table I), (ii) IND
(Einhorn et al., 1985; Williams et al., 1987) (Table II) and
(iii) RMH (Peckham, 1981) (Table III). Extent of metastatic
disease plus initial aFP and hCG were used to divide our
patients into the groups proposed by (iv) the MRC Working
Party on Testicular Tumours (1985) (Table IV). Extent of
disease, initial aFP and tumour histology were used to
separate our patients into prognostic groups proposed by (v)
EORTC (Stoter et al., 1987) (Table V). Based on initial
markers (aFP, hCG) only, patients were classified by (vi)
CXH tumour marker criteria (Newlands et al., 1986; Begent
Table I M.D. Anderson hospital classification of extent of disease
(MDA)
A Minimal pulmonary disease (no more than five lesions per
lung field, none>2cm diameter).
B Pulmonary disease more advanced than A, includes hilar and
mediastinal involvement.
C Minimal abdominal disease (abdominal involvement less than
D) with or without minimal pulmonary disease.
D Advanced abdominal disease (palpable abdominal mass,
obstructive uropathy, lateral ureteric diversion, liver
metastases) with or without pulmonary disease.
E Elevated marker (aFP, hCG) only.
F Central nervous system, bone or extra-abdominal lymph node
involvement.
A,C, E=minimal disease.
B, D, F =advanced disease.
Table II Indiana university staging system (IND)
Minimal extent
1. Elevated markers (aFP, hCG) only.
2. Cervical nodes (+/- non-palpable retroperitoneal nodes).
3. Unresectable non-palpable retroperitoneal disease.
4. <5 pulmonary metastases per lung field, largest <2cm
diameter (+/- non-palpable retroperitoneal nodes).
Moderate extent
1. Palpable abdominal mass only (no supradiaphragmatic
disease).
2. Moderate pulmonary metastases: 5-10 metastases per lung
field, largest <3cm diameter; or solitary pulmonary metastasis
of any size greater than 2cm diameter; mediastinal mass
<50% thoracic diameter (+/- non-palpable retroperitoneal
disease).
Advanced extent
1. Advanced pulmonary metastases: primary mediastinal germ
cell tumour or mediastinal mass >50% thoracic diameter;
> 10 pulmonary metastases per lung field or multiple
pulmonary metastases with largest diameter >3 cm (+/- non-
palpable retroperitoneal disease).
2. Palpable abdominal mass plus supradiaphragmatic disease.
3. Liver, bone or central nervous system metastases.
Table III Royal Marsden Hospital staging system (RMH)
I No clinical or radiologic evidence of metastases.
IM marker-positive only (aFP, hCG).
II Para-aortic node metastases:
A, <2cm maximum diameter.
B, 2-5cm maximum diameter.
C, >5cm maximum diameter.
III Supradiaphragmatic and infradiaphragmatic lymph node
involvement (subscripts A, B and C as above)
IV Extralymphatic metastases (subscripts A,B and C as
above):
L1, three or less lung metastases, none >2cm diameter.
L2, multiple lung metastases, none >2cm diameter.
L3, multiple metastases, one or more >2cm diameter.
H+, liver involvement.
CNS, central nervous system involvement.
OTH, other organ involvement, e.g. bone.
RMH disease extent
Small volume=IM, IIA, IIB, IIIA, IIIB, IVAL1, IVAL2, IVBL1
IVBL2
Large volume=IIc, IIIc, IVCL1, IVCL2, IVCL3, H', CNS,
OTH
Table IV Medical Research Council Working Party on Testicular
Tumours prognostic groups (MRC). (Basic staging per RMH
system, see Table III)
Disease extent
Small volume IM IIA, IIB, IIIA, IIIB, IVAL1, IVAL2, IVBLl,
IVBL2
Large volume IIC, IIIC, IVCLI, IVCL2
Very large volume L3 Lung disease, H+, CNS+, BONE'
Tumour marker levels
Low markers aFP <50kUl1 and hCG < 1,000IUI
High markers aFP >50kU11 and hCG > 1,000IUI
Risk catagories
Low risk Small volume+low markers
Large volume+low markers
Intermediate risk Small volume+high markers
Very large volume+low markers
Large volume+high markers
High risk Very large volume+high markers
Table V NSGCT prognostic groupings defined by the EORTC
(derived from analysis of 163 patients treated 1979-1983)
Trophoblast AFP level Lung
Risk group Survival present (kUl-1) metastases
I 100% No < 1,000 1
2 89% Yes < 1,000 1
No >1,000 1
No <1,000 0 or 2
3 41% Yes > 1,000 1
Yes < 1,000 0 or 2
No >1,000 0 or 2
No < 1,000 0 or 3
4 18% Yes >1,000 0, 2 or 3
Yes <1,000 3
No >1,000 3
Code for lung metastases: 0, none; 1, 1-3 metastases all <3cm
maximum diameter; 2, 4-19 metastases all <3cm maximum
diameter or 1-3 metastases if any >3cm maximum diameter; 3,
>20 metastases any size or 4-19 metastases if any >3cm
maximum diameter.
& Bagshawe, 1983) (serum aFP> 500kUI1 and/or serum
hCG>50,000 IUI1 =poor prognosis, lower values =good
prognosis).
Documentation of initial physical examination findings
was incomplete in a small number of cases but radiological
measurements of all original tumour dimensions were avail-
able. In these patients, we regarded -para-aortic masses
greater than 5cm diameter as palpable for this analysis. We238 R.N. HITCHINS et al.
Table VI Other definitions of poor prognosis, advanced or bulky
NSGCT
1. Daugaard & Rorth (1986)
> 10cm diameter abdominal mass; liver metastases;
supradiaphragmatic lymph node metastasis >5cm diameter;
multiple lung metastases with at least one >5cm diameter; serum
hCG >I00,000 IU -1; extragonadal primary with raised markers.
2. Ozols (1987)
> 1Ocm diameter abdominal or palpable mass; mediastinal mass;
pulmonary nodule >5cm diameter; >5 metastases per lung field
with at least one > 1 cm diameter; multiple lung nodules (>5
total) with at least one >2cm diameter; pleural effusion; hypoxia
(P02 <75mmHg); pure choriocarcinoma histology; extragonadal
primary; central nervous system involvement; liver or other
visceral metastases; aFP> 1,000 kUl-; hCG> 10,000IU 1 l.
3. Schmoll et al. (1987)
> 1Ocm diameter abdominal mass; >5 lung metastases with
diameter >2cm each; >20 lung metastases with diameter <2cm
each; mediastinal mass >5cm diameter; visceral, bone or central
nervous system metastases.
4. Pizzocaro et al. (1985)
> 10cm diameter abdominal mass, >5cm diameter pulmonary
nodule; liver, bone or central nervous system involvement;
aFP>l,OOOkUI-1; hCG>50,000IUl-.
believe masses of this size are palpable readily in the
NSGCT population consisting mainly of young non-obese
males. Para-aortic node masses were palpable in patients in
this series with radiological node dimensions less than 5cm
diameter.
Our patients who fulfilled the advanced disease, poor
prognosis or bulky disease criteria of Daugaard & Rorth
(1986), Ozols (1987) and Schmoll et al. (1987) were identi-
fied so outcome with these authors' regimens containing
ultra-high dose DDP could be compared with POMB/ACE.
Reclassification according to the far advanced disease cri-
teria of Pizzocaro et al. (1985) was performed to allow
comparison with a group receiving therapy based on conven-
tional dose DDP (100mgm-2). All these criteria are shown
in Table VI.
Survival curves were constructed by the method of Kaplan
& Meier (1958) and compared by log rank analysis (Mantel,
1966).
Results
Of the 206 patients, 13 were excluded from analysis because
of (i) unknown initial disease parameters or incomplete
staging (four patients), (ii) prior DDP-containing chemother-
apy (six patients), and (iii) adjuvant chemotherapy adminis-
tered after complete resection of metastatic disease in the
presence of normal tumour markers (three patients).
The remaining 193 patients were fully assessable. Median
age was 28 years (range 14-61). Histology (BTTP (18)) was
malignant teratoma undifferentiated in 101 cases (52%),
malignant teratoma intermediate in 53 (27%), malignant
teratoma trophoblastic in 20 (10%), malignant teratoma
differentiated in seven, seminoma in six and was unknown in
six cases. Twenty patients (10%) were marker-negative but
initial serum aFP was greater than 500kUl- in 35 cases
(18%) and initial serum hCG greater than 50,000IU1 1 in
20 cases (10%) (Germa-Lluch et al., 1980). Two patients
with unknown histology but serum hCG in excess of
100,000 IU11 at presentation were regarded as having tro-
phoblastic histology under the EORTC criteria (Table V).
All causes of death were included in subsequent survival
analyses and, in particular, no early deaths were excluded.
Twenty-two patients have died for an overall survival of
88.6% (171/193) at median follow-up 4.1 years (range 5 days
to 8.7 years). The survival in the 20 patients with extragona-
dal primaries was not very different from the whole group:
retroperitoneal primaries 7/12 (58%) and mediastinal prima-
ries 8/8 (100%) giving an overall survival of 15/20 (75%). A
specific and intractable problem in the retroperitoneal pri-
maries was duodenal involvement which resulted in three of
the deaths.
Figure 1 shows survival curves constructed after reclassifi-
cation of our patients by MDA criteria, Figure 2 IND
criteria, Figure 3 RMH criteria, Figure 4 MRC criteria,
Figure 5 EORTC criteria and Figure 6 by CXH tumour
marker criteria. Separation into MDA advanced disease
(P<0.02 compared with minimal) and CXH poor prognosis
(P<0.001 compared with good) groups was statistically
significant by log rank analysis of survival curves. By IND
classification, there was no statistical difference between
minimal and moderate (P>0.10) or between moderate and
advanced categories (P>0.10). However, if patients in IND
minimal and moderate categories were combined then com-
pared with those with IND advanced disease, significant
separation of survival curves occurred (P<0.005).
Division of our patients into small and large volume
groups by RMH criteria also resulted in significantly differ-
ent survival curves (P<0.02). Reclassification by MRC
criteria produced a well defined low risk group (P<0.01 low
compared with intermediate risk, P<0.001 low compared
with high risk) but no statistical difference was evident
between intermediate and high risk groups (P>0.10).
However, if high risk patients were compared with the
remainder, the difference was significant (P<0.05). Allo-
cation of our patients into four EORTC groups resulted in
similar survival curves for the first three categories but
significantly worse outcome in the fourth (P<0.02). All
curves showed similar separation if 16 patients who had
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Figure 1 Survival curves after reclassification by MDA criteria
into minimal (n =77) and advanced (n =116) disease.
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Figure 2 Survival curves after reclassification by IND criteria
into minimal (n =79), moderate (n=43) and advanced (n =71)
disease.
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Figure 3 Survival curves after reclassification by RMH criteria
into small (n =87) and large (n = 106) volume disease.
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Figure 6 Survival curves after reclassification by CXH tumour
marker criteria into good (n=135) and poor (n=58) prognosis
disease.
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Figure 4 Survival curves after reclassification by MRC criteria
into low (n =72), medium (n=67) and high (n= 54) risk disease.
n.s., no significant difference (log rank).
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Figure 5 Survival curves after reclassification by EORTC cri-
teria into four prognostic groups (1-4). n.s., no statistically
significant difference (log rank).
received prior radiotherapy were excluded from analysis,
although survival in each category was slightly better.
Figure 7 shows survival curves obtained when our patients
with advanced, poor prognosis, bulky or far advanced
disease defined by the criteria of Daugaard & Rorth (1986),
Ozols (1987), Schmoll et al. (1987) and Pizzocaro et al.
(1985) were compared. Table VII shows those authors'
treatment regimens and published results in comparison with
survival among our similarly defined adverse prognosis
patients treated with POMB/ACE at same duration of
follow-up.
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Figure 7 Survival curves of adverse prognosis patients accord-
ing to the definitions of (a) Ozols (1987) (n=113), (b) Pizzocaro
et al. (1985) (n=75), (c) Schmoll et al. (1987) (n=67) and (d)
Daugaard & Rorth (1986) (n=67). n.s., no statistically significant
difference (log rank).
Among 22 deaths in our series, the majority were recorded
in the most advanced groups under each classification system
or in the poor prognostic categories defined previously.
However, the size of these 'adverse prognosis' groups ranged
from 54 patients including 11 deaths (MRC high risk) to 116
patients including 19 deaths (MDA advanced). Therefore,
survival data were adjusted for group size with true positive
(TP) in each case regarded as the fraction dying in the
adverse prognosis group; true negative (TN) th 'fraction
alive in the favourable prognosis (remaining patients) group;
false positive (FP) the fraction alive in the adverse prognosis
group; and false negative (FN) the fraction dying in the
favourable prognosis group. Sensitivity and specificity of
each adverse prognosis definition in predicting death were
calculated (sensitivity=TP/(TP+FN) x 100%; specificity=
TN/(FP+TN) x 100%). Results are shown in Table VIII.
Sensitivity varied by no more than 10% (range 71-81%) and
specificity by less than 5% (range 52-56%) regardless of
definition of adverse prognosis and were not altered signifi-
cantly if deaths from intercurrent disease were excluded.
Seven deaths (32%) were noted two years or more after
commencement of first-line chemotherapy and four of these
fell into adverse prognostic groups by all definitions. A fifth
patient was poor prognosis by CXH criteria but favourable
prognosis under the other systems. The final two were both
in the MDA advanced disease group. One patient died from
myocardial infarction without evidence of residual NSGCT
but all other late deaths occurred in patients with relapsed
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Table VII Outcome after chemotherapy in poor prognosis, advanced or bulky NSGCT
CXH patients
Overall Median survival at
Reference and regimen used survival follow-up same follow-up
1. Daugaard & Rorth (1986) 24/33 (73%) 18.5 months 59/67 (88%)
DDP 40mgm 2 x 5 days (3-weekly)
VP16 200mgm-2 x 5 days (3-weekly)
BLM 15 mg m-2 weekly
2. Ozols (1987) 23/30 (77%) 27 months 99/113 (88%)
DDP 40mgm2x 5 days (3-weekly)
VP16 100 mg m-2 x 5 days (3-weekly)
VLB 0.2mgkg-1 (3-weekly)
BLM 30mg weekly
3. Schmoll et al. (1987) 69/98 (70%) 2.2 years 59/67 (88%)
DDP 35mgm-2 x 5 days (3-weekly)
VP16 120mgm2 x 5 days (3 weekly)
BLM 15 mgm2 weekly
4. Pizzocaro et al. (1985) 34/40 (85%) 2 years 63/75 (84%)
DDP 20mg m 2 x 5 days (3-weekly)
VP16 100mgm-2 x5 days (3-weekly)
BLM 18 mg m-2 weekly
Table VIII Sensitivity and specificity of various adverse
prognosis definitions in predicting death in patients with
NSGCT
Criteria for
adverse prognosis Sensitivity specifcity
MDA 81% 53%
IND 79% 54%
RMH 79% 53%
MRC 73% 54%
EORTC 76% 56%
CXH 80% 55%
Daugaard & Rorth (1986) 77% 54%
Ozols (1987) 71% 52%
Schmoll et al. (1987) 80% 55%
Pizzocaro et al. (1985) 77% 54%
(four) or persistent (two) NSGCT. Two of four relapsed
patients sustained their disease recurrence more than 12
months after completing first-line treatment in complete
remission. The two patients never rendered completely
disease-free had unresectable mature cystic teratoma in the
retroperitoneum. Active tumour, including cerebral metas-
tases, recurred in the first of these patients two years after
completion of first-line therapy and caused his demise. The
second patient's disease was controlled partially by various
treatments over a long period but he developed acute non-
lymphoblastic leukaemia and died more than 8 years after
the original diagnosis of metastatic NSGCT.
Discussion
These results imply that-a poor prognostic category can be
defined in metastatic NSGCT by initial serum marker (aFP,
hCG) levels alone at least as reliably as by more complicated
staging systems based on clinical and radiological measure-
ment of disease extent. The method is easy to use in clinical
practice and, because these markers reflect presence of the
NSGCT components of greatest lethal potential (yolk sac,
aFP; trophoblast, hCG (Paradinas, 1983), it is logical as
well. Long-term survival of 100% among our marker-
negative patients lends further support to this conclusion.
Multiple combinations and permutations of published
adverse prognostic criteria (Einhorn et al., 1985; Newlands et
al., 1986; Logothetis et al., 1986; Bosl et al., 1986; Daugaard
& Rorth, 1986; Ozols, 1987; Schmoll et al., 1987; Medical
Research Council Working Party on Testicular Tumours,
1985), only some of which are described in this paper, attest
to the lack of agreement on definition of advanced, bulky or
poor prognosis disease.
Chronologically, NSGCT deaths fall into two broad
groups: (a) early, from overwhelming and rapidly progressive
tumour at presentation; and (b) late, due to chemotherapy
resistance. Our data suggest all commonly used definitions of
adverse prognosis to have similar relatively modest sensiti-
vity and specificity in predicting long-term outcome although
early and late deaths were predicted equally. Long-term
survival must remain the ultimate criterion of successful
therapy in a highly responsive malignancy regardless of
reported improvements in response rate. Numerically larger
adverse prognostic groups (e.g. MDA: Ozols, 1987) included
patients classified as good prognosis by other criteria, caus-
ing apparent 'dilution' of results.
Late death remains a problem in NSGCT, especially
among poor prognosis patients. Many published series with
average follow-up of two to three years cannot hope to
address this (Williams et al., 1987; Logothetis et al., 1986;
Daugaard & Rorth, 1986; Ozols, 1987; Schmoll et al., 1987).
Seven of 22 deaths (32%) in our series were noted two years
or more from initiation of therapy and over half (12/22,
55%) occurred at more than 18 months. However, overall
survival among all our patients (88.6%) is at least as good as
any other published series and median follow-up is longer
(4.1 years) than most. Late relapses and disease-related
deaths after 5 years are also reported in long-term follow-up
of PVB (cisplatin, vinblastine, bleomycin) treated patients
from Indiana University (Greist et al., 1985). Most of our
late deaths were tumour-related although intercurrent causes
were seen as well as one fatality from probable treatment-
induced leukaemia. When we analysed these patients we
found that reduced rates of drug delivery during first-line
therapy were associated with subsequent relapse (Crawford
et al., 1988). Hence, intensifying frequency of drug administ-
ration in conventional dose regimens is a potential method
for improving survival among adverse prognosis patients
without resorting to high dose chemotherapy and subjecting
the patients to its extra toxicity.
Treatment results in adverse prognosis NSGCT must be
interpreted critically for the method of reporting results
(response rates rather than overall survival) as well as
duration of follow-up. Encouraging early results with new
and more toxic treatment regimens in advanced disease
categories may yield no better long-term outcome than
conventional therapies. Improved response rate and survival
in NSGCT have been demonstrated in a randomised study
with combination chemotherapy using DDP doses ofGERM CELL TUMOURS AND POMB/ACE 241
120mgm-2 opposed to 75mgm-2 (Samson et al., 1984).
The use of ultra-high dose DDP (175-200mgm-2 per
course) and VP16 regimens cause significant numbers of
toxic deaths (Ozols, 1987; Schmoll et al., 1987) and survival
actually appears worse than the results with POMB/ACE
(120mgm 2 DDP per course) (see Table IV). The results of
Pizzocaro et al. (1985) with conventional doses of DDP and
VP16 are similar to our own.
Bosl et al. (1983) performed a multivariate analysis of
prognostic variables which identified the concentration of
lactate dehydrogenase, hCG and the total number of metas-
tases as the major adverse prognostic variables. They used
these variables to identify a group of patients who received
alternating chemotherapy in an attempt to improve their
survival. However, although this was not a randomised
comparison there was no improvement in the results with
their approach (Bosl et al., 1987). More recently the same
group have performed a parallel analysis to that reported
here (Bajorin et al., 1988). In a smaller series ofpatients with
a shorter follow-up they have also identified the limitations
of current staging classifications. They found that there were
differences in sensitivity, specificity and predictive value in
the classifications they analysed. They included two systems
analysed in this report (IND and EORTC) and also reported
on their own system (Memorial Sloan-Kettering Cancer
Center (MSKCC)) and the National Cancer Institute (NCI)
systems. We agree with their conclusions that randomised
trials with agreed eligibility criteria for entry will be required
before conclusions on the relative efficacy of different regi-
mens of chemotherapy can be made.
I
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Appendix
POMB/ACE chemotherapy schedules
These chemotherapy schedules have been reported previously
(Newlands et al., 1986).
POMB
Day 1 Vincristine 1 mgm-2 intravenously; methotrexate
300mgm-2 as a 12h infusion.
Day 2 Bleomycin 15mg as a 24h infusion; folinic acid
rescue started at 24h after the start of
methotrexate in a dose of 15mg 12-hourly for
four doses.
Day 3 Bleomycin infusion 15mg by 24h infusion
Day 4 Cisplatin 12mgm2 as a 12h infusion, given
together with hydration and 3 g magnesium
sulphate supplementation.242 R.N. HITCHINS et al.
ACE
Etoposide (VP 16-213) 100mgm-2, days 1-5;
actinomycin D 0.5mg i.v. days 3,4 and 5;
cyclophosphamide 500mgm-2 i.v., day 5.
OMB
Day 1 Vincristine 1mgm-2 intravenously, methotrexate
300 mgm-2 as a 12h infusion.
Day 2 Bleomycin 15mg by 24h infusion: folinic acid
rescue started at 24h (after the start of
methotrexate) in a dose of 15mg 12-hourly for
four doses.
Day 3 Bleomycin 15mg by 24h infusion.
The sequence of treatment schedules is two courses of
POMB followed by ACE. POMB is then alternated with
ACE until patients are in biochemical remission as measured
by hCG and aFP (and, if raised, lactate dehydrogenase). The
usual number of courses of POMB has been three to five.
Following biochemical remission, patients alternate ACE
with OMB until remission has been maintained for approxi-
mately 12 weeks. The intervals between each course of
treatment have been kept to the minimum (usually 9-11
days). If delays are caused by myelosuppression following
courses of ACE, the first two days of etoposide are omitted
from subsequent courses of ACE. Unless there are delays
patients receive 360mgm-2 of cisplatinum in the first 8
weeks of therapy.
Central nervous system metastases
Prophylaxis. Most patients had pulmonary metastases at
presentation. Our current policy is to give CNS prophylaxis
with injections of intrathecal methotrexate 12.5mg with the
first three courses of chemotherapy if the patients have
pulmonary metastases and/or an initial serum
hCG> 1,000IU1-1. Cerebrospinal fluid (CSF) concent-
rations of hCG and aFP were measured routinely.
Established CNS metastases. The dose of methotrexate with
each course of POMB is increased to 1 gm-2 and infused
over 24h. Folinic acid rescue starts 8h later in a dose of
15mg 6-hourly for 72h. Intrathecal methotrexate in a dose
of 12.5mg is given with the courses of ACE and continued
until the brain metatases have completely regressed as mea-
sured by CT scanning and CSF HCG concentrations.
Dosage reduction in patients presenting with respiratory, liver
or renal failure. Rapid improvements can be obtained in
these very sick patients using a combination of etoposide
100mgm-2 i.v. and cisplatin (EP) 20mgm-2 i.v. on days 1
ans 2 (this can be increased to 3 days as indicated). These
courses are repeated at short intervals (5-7 drug free days)
and normally the full schedule with POMB/ACE can be
started after two or three courses of EP.